Ask the expert: Triple-negative breast cancer

featured_paragraph

Triple-negative breast cancer (TNBC) makes up about 10% to 15% of breast cancer diagnoses and tends to be more aggressive than other breast cancers.

general_content

Dr. Foluso Ademuyiwa answers questions about symptoms, side-effects, and treatment options for early-stage and metastatic TNBC.

on_this_page

About our speaker

Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI

Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI, is a breast medical oncologist and associate professor at Washington University in St. Louis. She is an expert in the management of all types of breast cancer. She provides patient-centered care as part of a multidisciplinary breast cancer team. Dr. Ademuyiwa is actively involved in research on triple-negative breast cancer and racial disparities in breast cancer research and serves as principal investigator on multiple clinical trials.

Learn more

Back to top

3 Tier Sponsors

Thank you to our sponsors

Signature

Benefactor

related_resources_article_carousel

Related resources

Triple-negative metastatic breast cancer

05/01/23 | BY: Rita Nanda

Metastatic triple-negative breast cancer is a rare form of aggressive breast cancer. Learn more its symptoms, diagnosis, and treatment options.

| 11 Min. Read | 1

Sacituzumab govitecan

02/03/23 | BY: Stephanie Graff

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with metastatic, triple-negative breast cancer and people diagnosed with metastatic breast cancer that is hormone receptor-positive and HER2-negative.

| 5 Min. Read | 8

Targeted therapy for triple-negative breast cancer

01/01/23 | BY: Zanetta Lamar

Learn more about the different classes of targeted therapies for triple-negative breast cancer, the tumor biomarkers that tell us who may benefit from them, and how they work.

| 4 Min. Read

Triple-negative

05/05/22 | BY: Reshma L. Mahtani

While some breast cancers express hormone receptors or have too many copies of the HER2 gene, other breast cancers may not have these characteristics. Triple-negative breast cancers (TNBC) do not express estrogen receptors, progesterone receptors, or HER2 receptors. About 10% to 15% of breast cancers are triple-negative.

| 13 Min. Read | 7

Follow-up care for TNBC

04/18/18 | BY: Lisa Carey

Learn what follow-up care may be needed and what it entails following a treatment for triple-negative breast cancer.

| 4 Min. Read | 6

Dealing with negative comments

04/18/18 | BY: Lisa Carey

Get tips on how to manage people who have opinions about your breast cancer treatment.

| 6 Min. Read